Company / FCF Margin
PALVELLA THERAPEUTICS, INC. FCF Margin History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-32.4%
FY2023
5-year range
-235.4% / -32.4%
FY2019-FY2023
Trend
+86.2%
vs FY2022
Sector context
#77 of 133
Health Care
What the data says
At -32.4%, PALVELLA THERAPEUTICS, INC.'s fcf margin ranks #77 of 133 in the Health Care sector. FCF Margin returned to growth in FY2023 after 2 years of decline, reaching -32.4%.
Based on SEC 10-K filings.
-32.4% in FY2023 with a 5-year CAGR of -221.6%.
Improved from -165.8% to -32.4% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +86.3pp
- 5-Year Change
- -221.6pp
- 10-Year Change
- -
Sector benchmark
#77 of 133 in Health CareTop 58% of 133This company -32.4% Sector average -632.8%
▼
+94.9% above sector average
Key checks
Key Insights
- In FY2023, fcf margin increased 86.2% year-over-year.
- Currently 600.4pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2018.
- Lowest fcf margin in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -32.4% | +86.2% |
| FY2022 | -235.4% | -42.0% |
| FY2021 | -165.8% | -39.7% |
| FY2020 | -118.7% | +0.0% |
| FY2019 | -118.7% | -162.8% |
| FY2018 | 189.1% | +173.8% |
| FY2017 | -256.3% | +0.0% |
| FY2016 | -256.3% | +43.6% |
| FY2015 | -454.5% | -8524.7% |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 30, 2026